Search Results
Your search for it matches 16118 pages
Showing 8651 - 8700Venetoclax Plus Rituximab Outperforms Standard Bendamustine Plus Rituximab in CLL
Venetoclax (Venclexta) plus rituximab (Rituxan)—a non–chemotherapy-containing regimen—was superior to standard-of-care bendamustine plus rituximab for patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to a final analysis of the phase III MURANO study reported at...
Expert Point of View: Renier J. Brentjens, MD, PhD
“The JULIET study, along with ZUMA-1, shows striking responses that are remarkably similar, even though there are differences in the signaling domains of both chimeric antigen receptor (CAR) T-cell products [tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta)],” said Renier J....
Update on CAR T-Cell ‘Breakthrough’ Therapy in Lymphoma
Primary analysis of the JULIET trial adds to mounting evidence that chimeric antigen receptor (CAR) T-cell therapy is effective for the treatment of lymphoma in patients with no other good treatment options. A single infusion of CAR T cells (CTL019) achieved durable remissions in almost 40% of...
Heterogeneity of the Estrogen Receptor and Risk of Death in Breast Cancer
Researchers at Karolinska Institutet in Sweden have discovered that the risk of death from breast cancer is twice as high for patients with high heterogeneity of the estrogen receptor within the same tumor, compared to patients with low heterogeneity. The study, published by Lindström et al in ...
Study Describes Structure of Tumor Herpes Virus Associated With Kaposi's Sarcoma
Researchers from the University of California, Los Angeles (UCLA) have provided the first description of the structure of the herpes virus associated with Kaposi’s sarcoma. The findings, published by Dai et al in Nature, answer important questions about how the virus spreads and provide a...
Expert Point of View: Andrzej Jakubowiak, MD, PhD
Andrzej Jakubowiak, MD, PhD, Director of the Multiple Myeloma Program at the University of Chicago Medical Center, commented on the study for The ASCO Post. “Overall, I was impressed with these results. They make an important contribution to the field. This is an advance in the right direction,”...
Trastuzumab-dkst Approved as Biosimilar to Trastuzumab
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 1, 2017, trastuzumab-dkst (Ogivri) was...
Expert Point of View: C. Kent Osborne, MD, FASCO and Lisa Carey, MD
C. Kent Osborne, MD, FASCO, Director of the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, who moderated a press briefing where the results were presented, called the findings “intriguing” but too premature for the clinic. “We don’t know what to do with the data ...
Circulating Tumor Cells May Predict Late Recurrence in Hormone Receptor–Positive Breast Cancer
In patients with early breast cancer, the presence in the blood of circulating tumor cells 5 years after diagnosis increases the risk for recurrence nearly 20-fold, researchers reported at the 2017 San Antonio Breast Cancer Symposium.1 “We found that a single positive circulating tumor cell assay...
Power of Pathologic Complete Response to Neoadjuvant Therapy Demonstrated in I-SPY 2 Trial
More evidence of the power of pathologic complete response (pCR) now comes from an update of the multicenter, adaptively randomized I-SPY 2 trial. In a study reported at the 2017 San Antonio Breast Cancer Symposium, pCR predicted for event-free and distant disease–free survival in high-risk...
Proof-of-Principle Study of Combination Checkpoint Inhibitor Plus Trastuzumab in HER2-Positive Advanced Breast Cancer
The combination of pembrolizumab (Keytruda) plus trastuzumab (Herceptin) may turn out to be a good treatment option for patients with trastuzumab-resistant advanced HER2-positive breast cancer, according to the results of an early study presented at the 2017 San Antonio Breast Cancer Symposium...
Expert Point of View: Virginia Kaklamani, MD and Harold Burstein, MD, PhD, FASCO
Press briefing moderator Virginia Kaklamani, MD, Professor of Medicine at The University of Texas Health Science Center, San Antonio, along with Harold Burstein, MD, PhD, FASCO, Associate Professor of Medicine at Harvard Medical School, commented on the National Surgical Adjuvant Breast and Bowel ...
NSABP B-47: No Benefit for Adjuvant Trastuzumab in HER2-Low Breast Cancer
For more than a decade, breast cancer experts have wondered whether women with low levels of HER2 might derive some benefit from trastuzumab (Herceptin), based on signals seen in earlier trastuzumab trials. Most notably, in the landmark National Surgical Adjuvant Breast and Bowel Project (NSABP) ...
Expert Point of View: Laurie Sehn, MD and Kenneth C. Anderson, MD
“We don’t think a lot about cutaneous T-cell lymphoma because it is one of the rare forms of lymphoma that we treat, but it is an extremely debilitating type of lymphoma,” said press briefing moderator Laurie Sehn, MD, Chair of the Lymphoma Tumour Group of the British Columbia Cancer Agency in...
Celebrating the Life of Jimmie Holland, MD
The oncology community mourns the sudden passing of Jimmie C. Holland, MD, who died on December 24, 2017, at the age of 89. Dr. Holland’s achievements over her 40-year career are legend. They include the founding of the subspecialty of psycho-oncology, the establishment of a full-time Psychiatry...
ECHELON-1: A Commendable Study, but Questions Remain
“The important thing is not to stop questioning. Curiosity has its own reason for existing.” —Albert Einstein The phase III international ECHELON-1 study, designed to evaluate brentuximab vedotin (Adcetris) as part of a front-line chemotherapy regimen for previously untreated advanced classic...
Expert Point of View: Howard “Skip” Burris III, MD, FACP, FASCO and Harold Burstein, MD, PhD, FASCO
Howard “Skip” Burris III, MD, FACP, FASCO, Chief Medical Officer and President of Clinical Operations at Sarah Cannon Cancer Center, Nashville, said the antibody-drug conjugates are especially attractive in triple-negative breast cancer. “We know chemotherapy is still effective in a large...
Novel Antibody-Drug Conjugate Active in Refractory Triple-Negative Breast Cancer
In relapsed or refractory triple-negative breast cancer, the antibody-drug conjugate sacituzumab govitecan (IMMU-132) demonstrated significant clinical activity in an open-label study presented at the 2017 San Antonio Breast Cancer Symposium.1 “Metastatic triple-negative breast cancer is an...
Competing Causes of Death vs Primary Disease in Survivors of Head and Neck Cancer
In a study reported in JAMA Oncology, Simpson et al found that each year of survival in patients with primary head and neck cancer was associated with a 26% increased risk of death from competing causes, and that competing causes predominated after 5 years postdiagnosis. Study Details The study...
FDA Accepts sBLA, Grants Priority Review for Tisagenlecleucel in Adults With DLBCL
Today, the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental Biologics License Application (sBLA) for tisagenlecleucel (Kymriah) suspension for intravenous infusion (formerly CTL019) for the treatment of adult patients with relapsed or refractory diffuse large...
Study Finds Association Between Breast Implants and Risk of Anaplastic Large Cell Lymphoma
In a Dutch study reported in JAMA Oncology, de Boer et al found that breast implants were associated with an increased risk of anaplastic large cell lymphoma (ALCL) in the breast, although the absolute risk was small. Study Details In the study, all patients diagnosed with primary non-Hodgkin...
Study Finds Adolescents Using Alternative Tobacco Products Are More Likely to Smoke 1 Year Later
Nonsmoking adolescents who use e-cigarettes, smokeless tobacco, or tobacco water pipes are more likely to start smoking conventional cigarettes within a year, according to new research by the University of California, San Francisco (UCSF). Findings were published by Watkins et al in JAMA...
Estrogen-Mimicking Compounds Found in Many Foods May Reduce Effectiveness of Breast Cancer Treatment
Scientists from The Scripps Research Institute (TSRI) have found that two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer. The study, published by Warth et al in Cell Chemical...
CAP Guideline Details HPV Testing in Head and Neck Carcinomas
Patients with certain head and neck cancers who test positive for high-risk types of human papillomavirus (HPV) have a better prognosis and may need less aggressive treatment. To help ensure that patients with these cancers are accurately diagnosed and effectively treated, the College of...
Study Finds Gene-Expression Profile Testing for Breast Cancer Less Cost-Effective in Real-World Practice
The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by scientists from Georgetown Lombardi Comprehensive Cancer Center. Their study, published by Chandler et al in the Journal...
Growing Socioeconomic and Racial Disparities in Management of Brain Metastases
Increasing use of a potentially life-saving treatment for metastatic cancer is leaving too many vulnerable patients behind, according to a new study from Yale Cancer Center/Smilow Cancer Hospital published by Kann et al in JNCCN – Journal of the National Comprehensive Cancer Network. The...
New Cancer Model Shows Genomic Link Between DCIS and IDC Breast Cancer Types
A new genetic-based model may explain how ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer, say researchers at The University of Texas MD Anderson Cancer Center. The study provides new insight into how DCIS leads to invasive ductal carcinoma (IDC) and provides a clearer...
Cancer Statistics 2018: U.S. Cancer Mortality Continues Decades-Long Drop
The cancer death rate dropped 1.7% from 2014 to 2015, continuing a drop that began in 1991 and has reached 26%, resulting in nearly 2.4 million fewer cancer deaths during that time. The data is reported in “Cancer Statistics, 2018,” the American Cancer Society’s...
Patients With SCLC Face Barriers to Receiving Standard-of-Care Treatment
Despite decades of clinical research establishing chemotherapy with thoracic radiation as the standard of care for the initial management of nonmetastatic small cell lung cancer (SCLC), a large percentage of U.S. patients do not receive these treatments, and in turn have lower overall survival,...
Treatment With Carfilzomib May Lead to Cardiovascular Toxicity in Patients With Multiple Myeloma
The proteasome inhibitor carfilzomib (Kyprolis) has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy may come with the risk of cardiovascular problems in a higher than expected...
Ribociclib Receives FDA Breakthrough Therapy Designation in Premenopausal Women With Hormone Receptor–Positive, HER2-Negative Breast Cancer
On January 3, ribociclib (Kisqali) received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer in combination with...
FDA Updates Nilotinib Label With Information on Discontinuing Treatment in Certain Patients With Early-Phase CML After Sustained Response
On December 22, the U.S. Food and Drug Administration (FDA) updated the product label for nilotinib (Tasigna) to include information for providers about how to discontinue the drug in certain patients. Nilotinib, first approved by the FDA in 2007, is indicated for the treatment of patients with...
Oncology World Mourns the Loss of Jimmie C. Holland, MD, Founder, Field of Psycho-Oncology
Jimmie C. Holland, MD, died suddenly on December 24, 2017, at the age of 89 years. Dr. Holland was the Attending Psychiatrist and Wayne E. Chapman Chair at Memorial Sloan Kettering (MSK) Cancer Center and Professor of Psychiatry, Weill Medical College of Cornell University in New York....
Harborside Partners With MAZ to Launch OncologyGo, Cancer Resource for Mobile Devices and TV
Media technology company, MAZ, has partnered with Harborside, a medical communications company based in Huntington, New York, to launch OncologyGo, a streaming-event coverage and video content app for specialists in oncology health care available on Apple TV, Roku, FireTV, and iOS. Harborside...
Is Medical Assistance in Dying Compassionate Care?
Suicidal ideation while receiving end-of-life cancer care is not unusual but can often be reversed by palliative and psychosocial oncology interventions. That said, there are patients who, even after intensive interventions, request medical assistance in dying. Physician-assisted death has been a...
Howard A. ‘Skip’ Burris III, MD, FACP, FASCO, Elected ASCO President for 2019–2020 Term
Howard A. “Skip” Burris III, MD, FACP, FASCO, a long-time member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2019. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2018. Additionally, five members were...
Expert Point of View: Eduardo Bruera, MD, FAAHPM
Eduardo Bruera, MD, FAAHPM, Medical Director, Department of Supportive Care Center, The University of Texas MD Anderson Cancer Center, in Houston, called the dyadic intervention “highly innovative.” “We all talk about movement, exercise, and the importance of physical activity for our patients,...
Helping Patients With Head and Neck Cancer and Their Caregivers Face Treatment-Associated Challenges
Head and neck cancer remains one of the most challenging clinical presentations faced by the oncology community. Patients must not only face a potentially lethal disease, but must also cope with treatments that often result in significant side effects. To gain a better understanding on the...
Samuel Oschin Comprehensive Cancer Institute Receives 3-Year Accreditation From ACS
The Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai has been honored with a 3-year accreditation with commendation from the American College of Surgeons (ACS). The accreditation is recognized by the National Cancer Institute, Centers for Medicare & Medicaid Services, the Joint...
Expect Questions About Link Between Alcohol and Cancer
With headlines such as “Cutting back on alcohol can prevent cancers”1 and “Even light drinking may raise your cancer risk,”2 media reports may be generating questions from patients about the ASCO statement summarizing evidence linking alcohol to an increased risk of cancer.3 “What I personally...
Oncologists Urged to Be Proactive in Advising Patients to Reduce Risk of Alcohol-Related Cancers
A recently released ASCO statement summarizing extensive evidence linking alcohol use to an increased risk of several leading cancers, including breast, colon, and head and neck, called on oncologists “as front-line providers for cancer patients” to help patients reduce excessive alcohol use.1...
Brentuximab Vedotin for Adult Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
On November 9, 2017, brentuximab vedotin (Adcetris) received regular approval for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides who have received prior systemic therapy.1,2 Supporting Efficacy Data Approval was based on...
Giving Back After Cancer
My diagnosis of neuroblastoma when I was 14 happened rather accidentally. I was a competitive dancer and very active in sports my first year in high school and had no symptoms of cancer or any illness. It wasn’t until my mother, who is a nurse, came into my room one morning to wake me for school...
Medical Oncologist Takes the Paths Less Traveled to Unwind and Reboot
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. For this installment in the Living a Full Life series of articles, Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer ...
The Puzzle Table
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Alectinib in ALK-Positive Metastatic Non–Small Cell Lung Cancer
On November 6, 2017, alectinib (Alecensa) received regular approval for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC), as detected by a U.S. Food and Drug Administration–approved test.1,2 Supporting Efficacy Data Approval was...
Gemtuzumab Ozogamicin in CD33-Positive Acute Myeloid Leukemia
On September 1, 2017, gemtuzumab ozogamicin (Mylotarg) was approved for treatment for newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and for treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients aged ≥ 2 years.1,2 It may be used in combination...
Data Must Be Generated to Support Cross-Labeling of Combination Therapies for Cancer
Combinations of targeted therapies (triple, quadruple, or even more) are part of the future of cancer treatment, which means that traditional clinical trials will have to be streamlined and updated to enable greater flexibility and to extract adequate safety and efficacy data. Problems inherent in...
FDA Helps Streamline Approval Process for Supplemental Drug Indications
As researchers learn more about the natural history of cancers, as more drugs are effective for more types of the disease, and as the number and complexity of combination therapies increase, the more important it is that new drugs and permutations of old ones be available to patients. The U.S. Food ...
WHAT SHOULD PUMA DO?
Puma should invest in developing an escalating-dose schedule for neratinib (Nerlynx). If one plans on giving a drug for a year, and starts after finishing a year of effective adjuvant therapy, there is no hurry to begin at full, intolerable doses. Starting at a lower dose and escalating slowly as...
